Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
暂无分享,去创建一个
Jia Fan | Marco Bongini | Andrea Lauterio | Matteo Cescon | V. Mazzaferro | A. Cucchetti | A. Pinna | M. Cescon | Jia Fan | Jian Zhou | A. Lauterio | Jian Zhou | Vincenzo Mazzaferro | Yi-feng He | Alessandro Cucchetti | Carlo Sposito | Antonio D Pinna | Stefano Di Sandro | Luciano De Carlis | He Yi-Feng | S. Di Sandro | L. De Carlis | C. Sposito | M. Bongini | He Yi-feng | L. D. De Carlis
[1] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[2] D. Markovic,et al. Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics , 2017, Annals of surgery.
[3] H. Pommergaard,et al. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis. , 2016, Transplantation reviews.
[4] R. Chung,et al. New perspectives for preventing hepatitis C virus liver graft infection , 2016, The Lancet. Infectious diseases.
[5] V. Mazzaferro. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach , 2016, Hepatology.
[6] J. Dufour,et al. Total tumor volume and alpha‐fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation , 2015, Hepatology.
[7] R. Hirose,et al. Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria , 2015, Hepatology.
[8] A. Israni,et al. OPTN/SRTR 2013 Annual Data Report: Liver , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] Thomas A. Gerds,et al. Concordance for prognostic models with competing risks , 2014, Biostatistics.
[10] Carmine Zoccali,et al. When do we need competing risks methods for survival analysis in nephrology? , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] S. Fan,et al. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. , 2013, Hepatobiliary surgery and nutrition.
[12] H. Hussain,et al. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. , 2013, Radiology.
[13] F. Roudot-thoraval,et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. , 2012, Gastroenterology.
[14] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[15] Patrick M M Bossuyt,et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.
[16] J. McCall,et al. Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. , 2011, Journal of hepatology.
[17] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[18] Alessandro Nanni Costa,et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[19] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[20] D. Samuel,et al. Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] S. Qiu,et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China , 2009, Journal of Cancer Research and Clinical Oncology.
[22] L. Mariani,et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.
[23] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[24] E. Steyerberg. Clinical Prediction Models , 2008, Statistics for Biology and Health.
[25] B. Daniele,et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .
[26] A. Venook,et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.
[27] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[28] V. Mazzaferro,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.
[29] K. Ishak,et al. Comparison of tumor pathology with duration of survival of north american patients with hepatocellular carcinoma , 1995, Cancer.
[30] T. Starzl,et al. Liver transplantation: an unfinished product. , 1989, Transplantation proceedings.